Measles virus in cancer therapy

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Oncolytic viruses are emerging as a promising cancer treatment strategy.
• Genetically modified herpesvirus (Talimogene laherparepvec) is approved for melanoma.
• Recombinant measles virus (MeV) is being developed as an oncolytic virus therapy.

Purpose of the Study:

• To evaluate the potential of recombinant measles virus (MeV) as an oncolytic virus for cancer treatment.
• To explore the genetic flexibility of MeV for developing targeted, armed, or shielded oncolytic viruses.
• To assess the safety and efficacy of MeV in preclinical and clinical settings.

Main Methods:

• Engineering of MeV strains with enhanced tumor specificity, efficacy, and resistance to serum neutralization.
• In vitro and in vivo testing of engineered MeV in cancer models.
• Conducting clinical trials to evaluate MeV therapy in patients with multiple myeloma and ovarian carcinoma.

Main Results:

• Engineered MeV strains demonstrate significant oncolytic potency and tumor specificity.
• Preclinical studies show remarkable efficacy and safety, including in non-human primates.
• MeV has entered 19 clinical trials, reaching Phase II for multiple myeloma and ovarian carcinoma.
• One patient with advanced myeloma achieved long-term remission.

Conclusions:

• Recombinant measles virus (MeV) represents a potent and safe oncolytic virus platform for cancer therapy.
• The genetic flexibility of MeV allows for tailored oncolytic virus development.
• Clinical trials indicate promising therapeutic potential for MeV in hematological and solid tumors.